{"id":"nesp","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Hypertension"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Dizziness"}]},"_chembl":{"chemblId":"CHEMBL1201566","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"NESP works by mimicking the action of endogenous erythropoietin, a hormone that regulates red blood cell production. This leads to an increase in red blood cell mass and hemoglobin levels, which can help alleviate anemia in patients with chronic kidney disease.","oneSentence":"NESP is a recombinant human erythropoietin analog that stimulates erythropoiesis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:22:51.702Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic kidney disease-related anemia"}]},"trialDetails":[{"nctId":"NCT07496463","phase":"PHASE2","title":"Setmelanotide to Treat Obesity in a Patient With Pseudohypoparathyroidism Type 1a (PHP1a)","status":"NOT_YET_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2026-04-01","conditions":"Pseudohypoparathyroidism Type 1a, Obesity","enrollment":1},{"nctId":"NCT07096297","phase":"PHASE2","title":"Luspatercept + Darbepoetin in MDS","status":"RECRUITING","sponsor":"Yale University","startDate":"2025-12-16","conditions":"MDS (Myelodysplastic Syndrome)","enrollment":60},{"nctId":"NCT06520826","phase":"PHASE3","title":"Vafseo Outcomes In-Center Experience","status":"ACTIVE_NOT_RECRUITING","sponsor":"USRC Kidney Research","startDate":"2024-11-20","conditions":"Anemia of Chronic Kidney Disease","enrollment":2200},{"nctId":"NCT06184867","phase":"NA","title":"Choices About Genetic Testing And Learning Your Risk With Smart Technology","status":"COMPLETED","sponsor":"Rutgers, The State University of New Jersey","startDate":"2023-09-26","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer","enrollment":50},{"nctId":"NCT05340465","phase":"PHASE2","title":"Darbe Plus IV Iron to Decrease Transfusions While Maintaining Iron Sufficiency in Preterm Infants","status":"RECRUITING","sponsor":"University of Washington","startDate":"2022-11-27","conditions":"Prematurity, Iron-deficiency, Iron Deficiency Anemia","enrollment":120},{"nctId":"NCT03329196","phase":"PHASE3","title":"Efficacy and Safety Study to Evaluate MT-6548 in Non-dialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japan","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2017-10-30","conditions":"Anemia; Non-dialysis Dependent Chronic Kidney Disease","enrollment":304},{"nctId":"NCT03439137","phase":"PHASE3","title":"Efficacy and Safety Study to Evaluate MT-6548 in Hemodialysis Subjects Currently Receiving ESAs With Anemia Associated With Chronic Kidney Disease in Japan","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2018-02-14","conditions":"Anemia; Hemodialysis Dependent Chronic Kidney Disease","enrollment":323},{"nctId":"NCT07300111","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of QLG1218(Daprodustat) in Chinese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD)","status":"NOT_YET_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2025-12-31","conditions":"Anaemia","enrollment":100},{"nctId":"NCT07169643","phase":"PHASE3","title":"Darbepoetin in Patients Candidates for Liver Transplant. (EPO-LT Trial)","status":"RECRUITING","sponsor":"Fundacion Clinic per a la Recerca Biomédica","startDate":"2025-11-25","conditions":"Liver Transplant; Complications","enrollment":140},{"nctId":"NCT03810911","phase":"PHASE2","title":"Mechanisms of EPO-induced Hypertension","status":"TERMINATED","sponsor":"VA Office of Research and Development","startDate":"2021-01-04","conditions":"Chronic Kidney Disease, Blood Pressure, Anemia","enrollment":27},{"nctId":"NCT07130487","phase":"NA","title":"Project CARE: CAncer Risk Evaluation","status":"RECRUITING","sponsor":"Anita Y. Kinney, PhD, RN","startDate":"2025-11-19","conditions":"Primary Care","enrollment":210},{"nctId":"NCT03169881","phase":"PHASE3","title":"Darbepoetin Trial to Improve Red Cell Mass and Neuroprotection in Preterm Infants","status":"COMPLETED","sponsor":"NICHD Neonatal Research Network","startDate":"2017-09-20","conditions":"Neurocognitive, Neuroprotective, Neonatal","enrollment":650},{"nctId":"NCT04798339","phase":"PHASE1, PHASE2","title":"Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2021-03-30","conditions":"Myelodysplastic Syndromes","enrollment":13},{"nctId":"NCT07025460","phase":"PHASE4","title":"Darbepoetin Alfa Once Monthly Dosing Schedule Maintains Hemoglobin Concentration Comparable to Every 2 Weeks Dosing Schedule in Advanced Chronic Kidney Disease Patients Not on Dialysis: A Multicenter, Phase 4 Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gangnam Severance Hospital","startDate":"2019-12-19","conditions":"Chronic Kidney Disease","enrollment":40},{"nctId":"NCT07131280","phase":"NA","title":"National Collaborative Centre for Hepatic Regenerative Medicine (NC-CHRM): Single vs Repeated Cycle of Granulocyte Colony-Stimulating Factor (GCSF) & Darbepoetin in Early Decompensated Cirrhosis","status":"NOT_YET_RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2025-09","conditions":"Decompensated Cirrhosis","enrollment":110},{"nctId":"NCT07119372","phase":"PHASE3","title":"Study of the Efficacy and Safety of BCD-131 and Mircera® in the Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis","status":"RECRUITING","sponsor":"Biocad","startDate":"2025-03-01","conditions":"Anemia, Chronic Kidney Disease, Chronic Kidney Disease Patients on Hemodialysis","enrollment":228},{"nctId":"NCT07002827","phase":"NA","title":"Effect of Single vs Repeated Cycles of a Combination of Granulocyte Colony Stimulating Factor and Darbepoetin vs Standard Medical Treatment on Immunometabolic Profile in Patient With Early Decompensated Cirrhosis.","status":"NOT_YET_RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2025-05-30","conditions":"Decompensated Liver Cirrhosis","enrollment":60},{"nctId":"NCT04313153","phase":"PHASE3","title":"Trial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and Three Times Weekly (TIW) for the Maintenance Treatment of Anemia in Hemodialysis Subjects Converting From Erythropoiesis-Stimulating Agents (ESAs)","status":"COMPLETED","sponsor":"Akebia Therapeutics","startDate":"2020-05-27","conditions":"Anemia","enrollment":319},{"nctId":"NCT06903559","phase":"PHASE1, PHASE2","title":"Roxadustat's Effect on Heart, Nutrition, and Inflammation in Hemodialysis Patients","status":"RECRUITING","sponsor":"Mansoura University","startDate":"2025-04-15","conditions":"Kidney Failure, Chronic, Malnutrition-Inflammation Syndrome, Anemia in End Stage Renal Disease","enrollment":46},{"nctId":"NCT06917950","phase":"PHASE1, PHASE2","title":"Roxadustat for Bone and Neuropsychiatric Aspects in Hemodialysis Patients","status":"RECRUITING","sponsor":"Mansoura University","startDate":"2025-04-15","conditions":"Kidney Failure,Chronic, Anemia in End Stage Renal Disease, Depression Anxiety Disorder","enrollment":46},{"nctId":"NCT05636891","phase":"PHASE1","title":"Pharmacokinetic/Pharmacodynamic Parameters of NNG-DEPO (Stimus) With Aranesp® (Amgen) in Treatment of Anemia in CKD Patients on Dialysis","status":"COMPLETED","sponsor":"Nanogen Pharmaceutical Biotechnology Joint Stock Company","startDate":"2021-09-19","conditions":"Chronic Kidney Disease","enrollment":43},{"nctId":"NCT05585645","phase":"PHASE3","title":"A Study to Compare Efficacy and Safety of Nanogen's Darbepoetin Alfa With Aranesp® (Amgen) in the Treatment of Anemia in Chronic Kidney Disease Patients on Dialysis (CKD)","status":"COMPLETED","sponsor":"Nanogen Pharmaceutical Biotechnology Joint Stock Company","startDate":"2019-08-08","conditions":"Anemia, Chronic Kidney Disease Requiring Chronic Dialysis","enrollment":214},{"nctId":"NCT01196715","phase":"PHASE3","title":"Comparison Study of Standard Care Against Combination of Growth Factors Agents for Low-risk Myelodysplastic Syndromes","status":"COMPLETED","sponsor":"Barts & The London NHS Trust","startDate":"2010-11-01","conditions":"Myelodysplastic Syndrome","enrollment":360},{"nctId":"NCT02278341","phase":"PHASE3","title":"Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable Dialysis","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2014-11-21","conditions":"Anemia, End Stage Renal Disease (ESRD)","enrollment":838},{"nctId":"NCT05810311","phase":"PHASE2","title":"The Effect of Roxadustat on Renal Oxygenation in Diabetes Nephropathy","status":"NOT_YET_RECRUITING","sponsor":"Region Stockholm","startDate":"2025-06-01","conditions":"Diabetes Complications, Diabetes; Nephropathy (Manifestation)","enrollment":30},{"nctId":"NCT02021318","phase":"PHASE3","title":"Roxadustat in the Treatment of Anemia in Chronic Kidney Disease (CKD) Patients, Not on Dialysis, in Comparison to Darbepoetin Alfa","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2014-03-12","conditions":"Anemia in Chronic Kidney Disease in Non-dialysis Patients","enrollment":616},{"nctId":"NCT02988973","phase":"PHASE3","title":"A Study of Intermittent Oral Dosing of ASP1517 in Non-Dialysis Chronic Kidney Disease Patients With Anemia","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2017-01-12","conditions":"Chronic Kidney Disease","enrollment":334},{"nctId":"NCT02952092","phase":"PHASE3","title":"A Study of Intermittent Oral Dosing of ASP1517 in Hemodialysis Chronic Kidney Disease Patients With Anemia","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2016-11-30","conditions":"Hemodialysis Chronic Kidney Disease Patients With Anemia","enrollment":303},{"nctId":"NCT01888445","phase":"PHASE2","title":"A Study to Investigate the Effect of ASP1517 After Intermittent Oral Dosing in Dialysis Chronic Kidney Disease Patients With Anemia Compared With Darbepoetin as a Reference Drug","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2013-03-28","conditions":"Renal Anemia Associated With Chronic Renal Failure (CRF)","enrollment":130},{"nctId":"NCT01471015","phase":"PHASE1, PHASE2","title":"Darbe Administration in Newborns Undergoing Cooling for Encephalopathy","status":"COMPLETED","sponsor":"University of Utah","startDate":"2012-09","conditions":"Hypoxic Ischemic Encephalopathy","enrollment":30},{"nctId":"NCT05265325","phase":"PHASE2","title":"A Study of AND017 to Treat Anemia in Chronic Kidney Disease Patients on Dialysis","status":"COMPLETED","sponsor":"Kind Pharmaceuticals LLC","startDate":"2023-05-03","conditions":"Renal Anemia","enrollment":175},{"nctId":"NCT06466785","phase":"PHASE3","title":"A Phase 3 Study of Efepoetin Alfa for Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis","status":"RECRUITING","sponsor":"Genexine, Inc.","startDate":"2024-01-25","conditions":"Anemia of Chronic Kidney Disease","enrollment":429},{"nctId":"NCT02876835","phase":"PHASE3","title":"Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-09-27","conditions":"Anaemia","enrollment":3872},{"nctId":"NCT03446612","phase":"PHASE2","title":"Anemia Study in Chronic Kidney Disease (CKD) : Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat -Forearm Blood Flow (ASCEND-FBF)","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2019-01-10","conditions":"Anaemia","enrollment":6},{"nctId":"NCT03457701","phase":"PHASE2","title":"Anemia Studies in CKD: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat- Iron (ASCEND: Fe)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2019-07-30","conditions":"Anaemia","enrollment":15},{"nctId":"NCT04432662","phase":"PHASE2","title":"Darbepoetin in Neonatal Encephalopathy Trial","status":"RECRUITING","sponsor":"Imperial College London","startDate":"2021-05-28","conditions":"Neonatal Encephalopathy","enrollment":150},{"nctId":"NCT05936021","phase":"NA","title":"Clinical Validation Study for Optimization of Anemia MAnagement in Hemodialysis Patients With End Stage Kidney Disease Using the Dialysis Anemia TReatmenT Model","status":"UNKNOWN","sponsor":"Intermountain Health Care, Inc.","startDate":"2023-07-01","conditions":"Dialysis","enrollment":80},{"nctId":"NCT02987465","phase":"","title":"Evaluating the Effect of Standard-of-care Erythropoiesis-stimulating Agents on Forearm Blood Flow in Nondialysis-dependent Subjects With Anaemia Associated With Chronic Kidney Disease.","status":"COMPLETED","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2017-02-20","conditions":"Cardiovascular Diseases, Chronic Kidney Disease","enrollment":29},{"nctId":"NCT04330729","phase":"NA","title":"The Effect of Salicylate on Platelet Function in CKD (Chronic Kidney Disease) Patients Treated With Aranesp","status":"RECRUITING","sponsor":"Zealand University Hospital","startDate":"2020-04-15","conditions":"Erythropoietin Adverse Reaction","enrollment":60},{"nctId":"NCT03071861","phase":"PHASE2","title":"Mild Encephalopathy in the Newborn Treated With Darbepoetin","status":"COMPLETED","sponsor":"University of New Mexico","startDate":"2017-12-01","conditions":"Neonatal Encephalopathy, Hypoxic-Ischemic Encephalopathy Mild","enrollment":28},{"nctId":"NCT03171818","phase":"PHASE2","title":"Darbepoetin for Ischemic Neonatal Stroke to Augment Regeneration","status":"UNKNOWN","sponsor":"UMC Utrecht","startDate":"2017-07-01","conditions":"PAIS, Neonatal Stroke, Perinatal Stroke","enrollment":80},{"nctId":"NCT05864261","phase":"PHASE4","title":"Pharmacokinetics Comparison Study of JT1801 and NESP® After Single Dose Administration in Chinese Health Male Volunteers","status":"COMPLETED","sponsor":"Yi Fang","startDate":"2023-05-15","conditions":"Renal Anemia","enrollment":74},{"nctId":"NCT01207778","phase":"","title":"Brain Imaging and Developmental Follow up of Infants Treated With Erythropoietin","status":"COMPLETED","sponsor":"University of New Mexico","startDate":"2010-03","conditions":"Prematurity","enrollment":77},{"nctId":"NCT00146562","phase":"PHASE2","title":"Pegfilgrastim and Darbepoetin Alfa in Support of Adjuvant Chemotherapy for Breast Cancer","status":"COMPLETED","sponsor":"Harold J. Burstein, MD, PhD","startDate":"2003-07","conditions":"Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer","enrollment":135},{"nctId":"NCT05768997","phase":"PHASE3","title":"High Dose IV Iron Plus ESA in Chemotherapy-induced Anemia","status":"UNKNOWN","sponsor":"Hallym University Medical Center","startDate":"2023-03-01","conditions":"Anemia","enrollment":312},{"nctId":"NCT05699109","phase":"","title":"Erythropoiesis Stimulating Agents for Anemia Management in Egyptian Hemodialysis Patients","status":"COMPLETED","sponsor":"Helwan University","startDate":"2021-01-01","conditions":"Anemia of Chronic Kidney Disease, Chronic Renal Failure, Chronic Renal Failure Anemia","enrollment":127},{"nctId":"NCT00858364","phase":"PHASE3","title":"Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy","status":"TERMINATED","sponsor":"Amgen","startDate":"2009-07-17","conditions":"Non-Small Cell Lung Cancer, Anemia, Cancer","enrollment":2549},{"nctId":"NCT00436748","phase":"PHASE3","title":"Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease","status":"TERMINATED","sponsor":"Amgen","startDate":"2008-09-16","conditions":"Anemia, Chronic Kidney Disease, Kidney Disease","enrollment":116},{"nctId":"NCT00093015","phase":"PHASE3","title":"Trial to Reduce Cardiovascular Events With Aranesp® Therapy (TREAT)","status":"COMPLETED","sponsor":"Amgen","startDate":"2004-08-01","conditions":"Kidney Disease, Diabetes Mellitus, Anemia","enrollment":4038},{"nctId":"NCT00358215","phase":"PHASE3","title":"RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial","status":"COMPLETED","sponsor":"Amgen","startDate":"2006-06-01","conditions":"Heart Failure, Anemia, Cardiovascular Disease","enrollment":2278},{"nctId":"NCT01652872","phase":"PHASE3","title":"Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease","status":"COMPLETED","sponsor":"Amgen","startDate":"2012-07-30","conditions":"Anemia in Chronic Kidney Disease Patients Not on Dialysis","enrollment":756},{"nctId":"NCT04484857","phase":"PHASE3","title":"Study of Roxadustat Conversion in Participants Receiving Stable ESA or as Initial Anemia Treatment in Hemodialysis Participants","status":"COMPLETED","sponsor":"Kyntra Bio","startDate":"2020-07-22","conditions":"Anemia Associated With End Stage Renal Disease","enrollment":283},{"nctId":"NCT02865850","phase":"PHASE3","title":"Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Participants With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD)","status":"COMPLETED","sponsor":"Akebia Therapeutics","startDate":"2016-07","conditions":"Anemia, Dialysis-Dependent Chronic Kidney Disease","enrollment":369},{"nctId":"NCT02892149","phase":"PHASE3","title":"Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Dialysis-dependent Chronic Kidney Disease (DD-CKD)","status":"COMPLETED","sponsor":"Akebia Therapeutics","startDate":"2016-08","conditions":"Anemia, Dialysis-Dependent Chronic Kidney Disease","enrollment":3554},{"nctId":"NCT02680574","phase":"PHASE3","title":"Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)","status":"COMPLETED","sponsor":"Akebia Therapeutics","startDate":"2016-02","conditions":"Anemia, Non-Dialysis-Dependent Chronic Kidney Disease","enrollment":1725},{"nctId":"NCT02648347","phase":"PHASE3","title":"Study to Evaluate Vadadustat for the Correction of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease","status":"COMPLETED","sponsor":"Akebia Therapeutics","startDate":"2015-12","conditions":"Anemia, Non-Dialysis-Dependent Chronic Kidney Disease","enrollment":1751},{"nctId":"NCT02879305","phase":"PHASE3","title":"Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-09-28","conditions":"Anaemia, Aspergillosis, Allergic Bronchopulmonary","enrollment":2964},{"nctId":"NCT04012957","phase":"PHASE3","title":"Desidustat in the Treatment of Anemia in CKD","status":"COMPLETED","sponsor":"Zydus Lifesciences Limited","startDate":"2019-07-20","conditions":"Chronic Kidney Disease Stage 3, Anemia, Chronic Kidney Disease Stage 4","enrollment":588},{"nctId":"NCT02273726","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable Dialysis","status":"COMPLETED","sponsor":"Kyntra Bio","startDate":"2015-01-15","conditions":"CKD Anemia in Stable Dialysis Patients","enrollment":741},{"nctId":"NCT03029208","phase":"PHASE3","title":"Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-in Incident Dialysis (ASCEND-ID)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-05-11","conditions":"Anaemia","enrollment":312},{"nctId":"NCT00153868","phase":"PHASE4","title":"A Web-based Study of Quality of Life Benefits Associated Aranesp in Anemic Patients With Cancer","status":"COMPLETED","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2003-10","conditions":"Anemia, Cancer","enrollment":43},{"nctId":"NCT00642967","phase":"PHASE3","title":"A Study of Subcutaneous Mircera for the Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease Not on Dialysis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-06","conditions":"Anemia","enrollment":127},{"nctId":"NCT00717821","phase":"PHASE3","title":"A Study of Once Monthly Intravenous or Subcutaneous Mircera in Participants With Chronic Kidney Disease on Hemodialysis.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-08","conditions":"Anemia","enrollment":421},{"nctId":"NCT01506947","phase":"PHASE4","title":"A Pilot Clinical Study Evaluating the Effect of Parathyroid Hormone (PTH) Lowering On Erythropoietin Consumption in Calcitriol-Resistant Patients","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2012-05-10","conditions":"Moderate to Severe Secondary Hyperparathyroidism, Stage 5 Chronic Kidney Diseases","enrollment":65},{"nctId":"NCT04959578","phase":"PHASE4","title":"Comparison of Darbepoetin Alpha and Recombinant Human Erythropoietin for Treatment of Anemia in Children With Chronic Kidney Disease","status":"COMPLETED","sponsor":"Rufaida Mazahir","startDate":"2018-02-01","conditions":"Anemia of Chronic Kidney Disease","enrollment":50},{"nctId":"NCT02241200","phase":"PHASE1","title":"A Study in Healthy Volunteers to Compare the Profiles of DA-3880 and EU Sourced ARANESP® (Amgen)","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2014-08-18","conditions":"Symptomatic Anemia","enrollment":64},{"nctId":"NCT03761290","phase":"","title":"Glucose Homeostasis in Pseudohypoparathyroidism","status":"TERMINATED","sponsor":"Vanderbilt University Medical Center","startDate":"2019-06-19","conditions":"Pseudohypoparathyroidism and Pseudopseudohypoparathyroidism, Pseudohypoparathyroidism Type Ia, Albright Hereditary Osteodystrophy","enrollment":14},{"nctId":"NCT04027517","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of JTZ-951 Compared to Darbepoetin Alfa in Korean Renal Anemia Patients Receiving Hemodialysis.","status":"COMPLETED","sponsor":"JW Pharmaceutical","startDate":"2019-01-15","conditions":"Anemia of Chronic Kidney Disease","enrollment":172},{"nctId":"NCT03519243","phase":"PHASE2","title":"Comparative Study of the Efficacy and Safety of BCD-131 and Mircera in Treatment of Anemia in CKD Patients on Dialysis","status":"COMPLETED","sponsor":"Biocad","startDate":"2017-10-24","conditions":"Anemia","enrollment":75},{"nctId":"NCT03543657","phase":"PHASE3","title":"Maintenance Treatment of Renal Anemia in Dialysis Subjects","status":"COMPLETED","sponsor":"Bayer","startDate":"2018-06-23","conditions":"Anemia, Renal Insufficiency, Chronic","enrollment":229},{"nctId":"NCT03350321","phase":"PHASE3","title":"A Study of Molidustat for Correction of Renal Anemia in Non-dialysis Subjects","status":"COMPLETED","sponsor":"Bayer","startDate":"2017-12-12","conditions":"Anemia, Renal Insufficiency, Chronic","enrollment":162},{"nctId":"NCT03350347","phase":"PHASE3","title":"A Study of Molidustat for Maintenance Treatment of Renal Anemia in Non-dialysis Subjects","status":"COMPLETED","sponsor":"Bayer","startDate":"2017-12-13","conditions":"Anemia, Renal Insufficiency, Chronic","enrollment":164},{"nctId":"NCT02969655","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of Daprodustat Compared to Darbepoetin Alfa in Japanese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-11-21","conditions":"Anaemia","enrollment":271},{"nctId":"NCT00058422","phase":"PHASE2","title":"Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2003-02-10","conditions":"Lymphoma","enrollment":65},{"nctId":"NCT03992066","phase":"PHASE1","title":"Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease","status":"COMPLETED","sponsor":"Akebia Therapeutics","startDate":"2019-05-28","conditions":"Anemia Associated With Chronic Kidney Disease","enrollment":46},{"nctId":"NCT00070382","phase":"PHASE3","title":"Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer","status":"COMPLETED","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2003-08","conditions":"Anemia, Leukemia, Lymphoma","enrollment":14},{"nctId":"NCT02136563","phase":"","title":"Renal Prognosis in Chronic Kidney Disease Patients With Hyporesponsive Anemia to Erythropoiesis Stimulating Agents","status":"COMPLETED","sponsor":"Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan","startDate":"2014-04","conditions":"Renal Anemia, Chronic Kidney Disease","enrollment":2000},{"nctId":"NCT00883415","phase":"","title":"Myocardial Glucose Uptake (MGU) in Patients With Chronic Kidney Disease","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2008-05","conditions":"Cardiomyopathy, Chronic Kidney Disease, Anemia","enrollment":20},{"nctId":"NCT02506868","phase":"PHASE3","title":"Safety and Efficacy Study of BCD-066 Compared to Aranesp® for Anemia Treatment in Chronic Kidney Disease Patients","status":"COMPLETED","sponsor":"Biocad","startDate":"2015-08-08","conditions":"Chronic Kidney Disease, End Stage Renal Failure on Dialysis, Anemia","enrollment":196},{"nctId":"NCT03693950","phase":"PHASE1","title":"The Study of PK, PD, Safety of Multiple Intravenous Injections of BCD-066 and Aranesp in Healthy Volunteers","status":"COMPLETED","sponsor":"Biocad","startDate":"2017-03-28","conditions":"Healthy","enrollment":57},{"nctId":"NCT02890602","phase":"PHASE2","title":"Erythropoietin for Management of Anemia Caused by Chemotherapy","status":"COMPLETED","sponsor":"Kosin University Gospel Hospital","startDate":"2012-09-01","conditions":"Diffuse Large B-cell Lymphoma","enrollment":53},{"nctId":"NCT03104426","phase":"PHASE2, PHASE3","title":"EPO-4-Rhesus Study","status":"UNKNOWN","sponsor":"Sanquin-LUMC J.J van Rood Center for Clinical Transfusion Research","startDate":"2017-10-31","conditions":"Erythroblastosis, Fetal, Erythroblastosis Fetalis, Rh Disease, Erythroblastosis Fetalis Due to RH Antibodies","enrollment":42},{"nctId":"NCT02021409","phase":"PHASE2","title":"Maintenance Treatment of Anemia in Pre-dialysis Subjects With Chronic Kidney Disease on Darbepoetin Treatment Versus BAY85-3934","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-01-28","conditions":"Anemia, Renal Insufficiency, Chronic","enrollment":126},{"nctId":"NCT02817555","phase":"PHASE4","title":"Cost Comparison Study of Darbepoetin Versus Epoetin Therapy to Treat Anemia in Hemodialysis Patients","status":"COMPLETED","sponsor":"Andrea L Woodland","startDate":"2010-09","conditions":"Anemia, Chronic Kidney Disease","enrollment":50},{"nctId":"NCT00773513","phase":"PHASE4","title":"A Study to Assess All-Cause Mortality and Cardiovascular Morbidity in Participants With Chronic Kidney Disease (CKD) on Dialysis and Those Not on Renal Replacement Therapy Receiving Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) or Reference Erythropoietin Stimulating Agents (ESAs)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-12-12","conditions":"Chronic Renal Anemia","enrollment":2825},{"nctId":"NCT02731469","phase":"PHASE1","title":"Study of Pharmacokinetics, Pharmacodynamics, Safety of BCD-131 Compared to Mircera and Aranesp in Healthy Volunteers","status":"COMPLETED","sponsor":"Biocad","startDate":"2016-06-15","conditions":"Reticulocyte Count","enrollment":45},{"nctId":"NCT02912494","phase":"PHASE3","title":"A Phase III Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)","status":"COMPLETED","sponsor":"Kissei Pharmaceutical Co., Ltd.","startDate":"2016-09","conditions":"Anemia","enrollment":""},{"nctId":"NCT03861637","phase":"NA","title":"Impact of Full Correction of PTA in Renal Transplant Recipients","status":"COMPLETED","sponsor":"Hamid Al-Essa Organ Transplant Center","startDate":"2015-01-20","conditions":"Anemia","enrollment":280},{"nctId":"NCT00334737","phase":"PHASE2","title":"Darbepoetin Administration to Preterm Infants","status":"COMPLETED","sponsor":"University of New Mexico","startDate":"2006-06","conditions":"Infant, Newborn","enrollment":102},{"nctId":"NCT03776032","phase":"PHASE3","title":"A Novel Erythropoiesis Stimulating Protein (NESP; Darbopoetin Alfa) for the Treatment of Anemia in Lung Cancer Patients Receiving Multi-cycle Platinum-Containing Chemotherapy","status":"COMPLETED","sponsor":"Amgen","startDate":"1999-09-14","conditions":"Anemia","enrollment":320},{"nctId":"NCT02175277","phase":"PHASE3","title":"Darbepoetin Alfa MDS Companion Protocol","status":"COMPLETED","sponsor":"Amgen","startDate":"2014-06-12","conditions":"Myelodysplastic Syndrome (MDS)","enrollment":9},{"nctId":"NCT00283621","phase":"NA","title":"Aranesp and Neulasta in Patients With Sarcoma Receiving Adriamycin and Ifosfamide","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2003-06-02","conditions":"Sarcoma","enrollment":51},{"nctId":"NCT03242967","phase":"PHASE3","title":"Study to Evaluate Three Times Per Week (TIW) Oral Dosing of Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD)","status":"WITHDRAWN","sponsor":"Akebia Therapeutics","startDate":"2017-08","conditions":"Anemia, Dialysis-Dependent Chronic Kidney Disease","enrollment":""},{"nctId":"NCT01977573","phase":"PHASE2","title":"A Study to Evaluate Safety and Efficacy of GSK1278863 in Non-Dialysis Dependent (NDD) Subjects With Anemia Associated With Chronic Kidney Diseases (CKD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-10-31","conditions":"Anaemia","enrollment":252},{"nctId":"NCT00398047","phase":"PHASE2","title":"Azacitidine, Darbepoetin Alfa, and Erythropoietin and Filgastrim (G-CSF) in Treating Patients With Myelodysplastic Syndromes","status":"TERMINATED","sponsor":"Wake Forest University Health Sciences","startDate":"2006-09","conditions":"Leukemia, Myelodysplastic Syndromes","enrollment":3},{"nctId":"NCT00642304","phase":"PHASE3","title":"A Study of Subcutaneous C.E.R.A. for the Maintenance of Hemoglobin Levels in Participants With Chronic Renal Anemia Not on Dialysis.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-03-27","conditions":"Anemia","enrollment":20},{"nctId":"NCT02439697","phase":"NA","title":"A Cohort Study of Conversion From Aranesp® to NESP® for the Treatment of Anemia in Dialysis Patients","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2015-11","conditions":"Anemia, End Stage Renal Failure on Dialysis","enrollment":50},{"nctId":"NCT03542916","phase":"PHASE1","title":"Pharmacokinetics Study of CJ-40001 and NESP® After Single Dose Administration in Health Male Volunteers","status":"COMPLETED","sponsor":"HK inno.N Corporation","startDate":"2014-10","conditions":"Healthy Subjects","enrollment":56},{"nctId":"NCT00281892","phase":"PHASE3","title":"Fludarabine and Darbepoetin Alfa in Treating Older Patients With Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"German CLL Study Group","startDate":"2004-09","conditions":"Chronic Lymphocytic Leukemia, Anemia","enrollment":97},{"nctId":"NCT01581073","phase":"PHASE3","title":"PRevention of End Stage Kidney Disease by Darbepoetin Alfa In Chronic Kidney Disease Patients With nondiabeTic Kidney Disease","status":"COMPLETED","sponsor":"Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan","startDate":"2012-02-16","conditions":"Chronic Kidney Disease, Diabetes","enrollment":476}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Aranesp","Darbepoetin alfa"],"phase":"phase_3","status":"active","brandName":"NESP","genericName":"NESP","companyName":"Genexine, Inc.","companyId":"genexine-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"NESP is a recombinant human erythropoietin analog that stimulates erythropoiesis. Used for Chronic kidney disease-related anemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}